CD8A and neoplasm: Blockade of LILRB4 enhances tumor immune infiltrates, rebalances effector to regulatory T cell ratios, and modulates TAM phenotypes toward a less suppressive state, promoting the transformation of CD4+ T cells into Th1 effectors and CD8+ T cells into less exhausted states [108].